Novo Nordisk Share Price Target 2025: Technical Outlook & Analyst Forecasts
Novo Nordisk (NYSE: NVO) is currently trading near $51, with analysts offering mixed forecasts for 2025. While some brokerages, including UBS and BofA, have trimmed their targets to $48–$53, broader consensus estimates suggest potential upside toward $90–$94. Technical charts show strong support around $36, with resistance at $60–$78, making these key levels to watch. Recent FDA approval of Wegovy for MASH treatment has supported short-term gains, but rising competition from Eli Lilly and lowered company guidance pose challenges. Investors remain divided, with 2025 targets ranging widely between $48 and $94.
Quick Highlights
-
Current Price (ADS): ~$51
-
Analyst Consensus: ~$93.67 (≈83% upside)
-
Zacks Range: $54 – $112 (avg. ~$70.88)
-
UBS Target: 340 DKK (~$48, Neutral)
-
BofA Target: 375 DKK (~$53, Neutral)
-
Key Technical Levels: Support $36 | Resistance $60–$78
Recent Market Moves
-
FDA Boost: Wegovy cleared for MASH treatment, shares gained ~4–6%.
-
Broker Downgrades: UBS & BofA cut targets, citing strong competition.
-
Trend Warning: Stock down ~60% since 2024 highs; guidance lowered.
-
Leadership Shift: New CEO faces pressure in the U.S. market.
Technical Analysis
-
Support Zone: $36 (critical floor).
-
Resistance Zones: $60 and $78 (historical ceilings).
-
Momentum: 50-week MA nearing 200-week MA → possible “death cross.”
Novo Nordisk Share Price Target 2025
| Scenario | Target Range (USD) | Key Factors |
|---|---|---|
| Bullish | $90 – $94 | Strong GLP-1 growth, FDA approvals |
| Base Case | $54 – $72 | Analyst averages, moderate growth |
| Conservative | $48 – $53 | UBS & BofA neutral stance |
| Bearish | Below $36 | Support break + competitive risks |
Key Risks to Watch
-
Rising Eli Lilly competition in GLP-1 drugs.
-
Guidance cut: Growth trimmed to 8–14% for 2025.
-
Leadership changes could impact strategic direction.
Novo Nordisk is trading near $51 today. Analysts remain divided: optimistic forecasts suggest upside toward $94, while cautious targets sit closer to $48–$53.
Technically, holding above $36 is crucial. A breakout past $60 could unlock $78, while failure below support risks deeper downside.
